 |
52 Diseases |  |
1 Trial |
|
1 Trial |  |
298 News |  |
| «12345 |
- luminespib (AUY922) / Ligand, Herceptin (trastuzumab) / Roche
Enrollment closed: Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab (clinicaltrials.gov) - Oct 9, 2012
P1, N=45, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting
- luminespib (AUY922) / Ligand
Trial withdrawal: AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=0, Withdrawn, Sponsor: Texas Tech University Health Sciences Center
Recruiting --> Active, not recruiting Recruiting --> Withdrawn
- luminespib (AUY922) / Ligand
Enrollment change: AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=0, Withdrawn, Sponsor: Texas Tech University Health Sciences Center
Recruiting --> Withdrawn N=49 --> 0
- | luminespib (AUY922) / Ligand
Enrollment change, Combination therapy: A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. (clinicaltrials.gov) - Sep 24, 2012
P1/2, N=38, Completed, Sponsor: Novartis Pharmaceuticals
N=49 --> 0 N=29 --> 38
- | luminespib (AUY922) / Ligand
Trial completion, Combination therapy: A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. (clinicaltrials.gov) - Sep 24, 2012
P1/2, N=38, Completed, Sponsor: Novartis Pharmaceuticals
N=29 --> 38 Terminated --> Completed
- | luminespib (AUY922) / Ligand
Enrollment open: A Study of the HSP90 Inhibitor AUY922 (clinicaltrials.gov) - Sep 6, 2012
P2, N=42, Recruiting, Sponsor: M.D. Anderson Cancer Center
Terminated --> Completed Not yet recruiting --> Recruiting
- luminespib (AUY922) / Ligand, Avastin (bevacizumab) / Roche
Enrollment change: Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET) (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=7, Completed, Sponsor: University Medical Centre Groningen
Not yet recruiting --> Recruiting N=11 --> 7
- luminespib (AUY922) / Ligand, Avastin (bevacizumab) / Roche
Trial completion: Imaging HSP90 Inhibitor AUY922 on VEGF-89ZR-bevacizumab Positron Emission Tomography (PET) (clinicaltrials.gov) - Sep 4, 2012
P=N/A, N=7, Completed, Sponsor: University Medical Centre Groningen
N=11 --> 7 Recruiting --> Completed
- luminespib (AUY922) / Ligand
Enrollment closed, Metastases: A Study of the Hsp90 Inhibitor AUY922 Plus Capecitabine for the Treatment of Patients With Advanced Solid Tumors (clinicaltrials.gov) - Aug 19, 2012
P1, N=23, Active, not recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Completed Recruiting --> Active, not recruiting
- | luminespib (AUY922) / Ligand
New P2 trial: HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET (clinicaltrials.gov) - Aug 15, 2012
P2, N=25, Recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
- |||| luminespib (AUY922) / Ligand
Trial completion: Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients (clinicaltrials.gov) - Aug 15, 2012
P1/2, N=117, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | luminespib (AUY922) / Ligand
New P2 trial: An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations (clinicaltrials.gov) - Jul 18, 2012
P2, N=108, Recruiting, Sponsor: Novartis Pharmaceuticals
- | luminespib (AUY922) / Ligand
Enrollment open, Metastases: Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy (clinicaltrials.gov) - Jun 6, 2012
P2, N=37, Recruiting, Sponsor: University Health Network, Toronto
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Piqray (alpelisib) / Novartis
New P1 trial, Combination therapy, Metastases: PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer (clinicaltrials.gov) - Jun 5, 2012
P1, N=41, Recruiting, Sponsor: Novartis Pharmaceuticals
- luminespib (AUY922) / Ligand
New P1 trial, Metastases: Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies (clinicaltrials.gov) - May 17, 2012
P1, N=2, Terminated, Sponsor: Dale Shepard, MD, PhD
- luminespib (AUY922) / Ligand, Herceptin (trastuzumab) / Roche
Trial completion: AUY922: 89Zr-trastuzumab PET for Imaging the Effect of HSP90 Inhibition (clinicaltrials.gov) - Mar 19, 2012
P1, N=7, Completed, Sponsor: University Medical Centre Groningen
Not yet recruiting --> Recruiting Recruiting --> Completed
- | luminespib (AUY922) / Ligand
Trial initiation date, Stroma: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Dec 12, 2011
P2, N=34, Recruiting, Sponsor: SCRI Development Innovations, LLC
Recruiting --> Completed Initiation date: Jul 2011 --> Oct 2011
- | luminespib (AUY922) / Ligand
Enrollment open, Stroma: Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor (clinicaltrials.gov) - Dec 12, 2011
P2, N=34, Recruiting, Sponsor: SCRI Development Innovations, LLC
Initiation date: Jul 2011 --> Oct 2011 Not yet recruiting --> Recruiting
- | luminespib (AUY922) / Ligand
New P2 trial: A Study of the HSP90 Inhibitor AUY922 (clinicaltrials.gov) - Dec 1, 2011
P2, N=42, Recruiting, Sponsor: M.D. Anderson Cancer Center
- | luminespib (AUY922) / Ligand
New P2 trial, Metastases: Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy (clinicaltrials.gov) - Nov 30, 2011
P2, N=37, Recruiting, Sponsor: University Health Network, Toronto